CN104292175B - Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use - Google Patents
Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use Download PDFInfo
- Publication number
- CN104292175B CN104292175B CN201410525880.4A CN201410525880A CN104292175B CN 104292175 B CN104292175 B CN 104292175B CN 201410525880 A CN201410525880 A CN 201410525880A CN 104292175 B CN104292175 B CN 104292175B
- Authority
- CN
- China
- Prior art keywords
- compound
- present
- preparation
- formula
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the drug world relevant to hyperuricemia and gout。Specifically, the present invention relates to uric acid transporter body 1 inhibitor of the class tetrazoleacetic acid structure containing nitro, its preparation method and pharmaceutical composition and their application in preparing diabetes medicament containing them。Wherein, R1Selected from H, C1-C5Alkyl, C3-C6Cycloalkyl。
Description
Technical field
The present invention relates to the drug world that treatment hyperuricemia is relevant with gout。Specifically, the present invention relates to hyperuricemia and gout medicative class uric acid transporter body 1 (uratetransporter1, the URAT1) inhibitor of tetrazoleacetic acid structure containing nitro, preparation method, containing they pharmaceutical composition and in purposes pharmaceutically。
Background technology
Gout is a kind of chronic metabolic disease, and the pain being deposited on the positions such as joint and causing with hyperuricemia and monosodium urate salt (MSU) is for principal character, and main cause is purine metabolic disturbance and/or uric acid excretion disorder。According to estimates, whole world patient with gout has more than 2,000 ten thousand at present。The medicine being currently used for treatment gout includes for lenitive anti-inflammatory drug (such as colchicine etc.), suppresses uricopoiesis medicine (xanthine oxidase inhibitor being representative with allopurinol and Febuxostat), thick urate excretion medicine (the urate excretion medicine being representative with probenecid, sulphinpyrazone, benzbromarone and losartan) and uricase (with pegloticase for representative)。There is the toxic and side effects of different degree in these medicines, as benzbromarone has the danger causing explosive hepatitis, allopurinol has liver and the untoward reaction such as bone marrow toxicity and allergy, etc.。
Lesinurad (RDEA594) a kind of can be suppressed uric acid transporter body (uratetransporter1 in kidney by what Ardea company developed, URAT1) discharged the oral drugs of uric acid in blood by the approach of urine, be currently in III phase clinical stage。The antiviral drugs RDEA806 that Lesinurad is researched and developed by Valeant company the earliest develops。The proprietary rights of present Lesinurad is purchased due to Ardea company at present and is belonged to AstraZeneca。
The invention discloses the URAT1 inhibitor of the class tetrazoleacetic acid structure containing nitro, these compounds can be used for the medicine of preparation treatment hyperuricemia and gout。
Summary of the invention
It is an object of the present invention to provide one and there is excellent activity, there is a compounds of formula I。
It is a further object to provide the method that preparation has the compound of formula I。
It is also another object of the present invention to provide the compound containing formula I as effective ingredient, and the Pharmaceutical composition of one or more pharmaceutically acceptable carriers, excipient or diluent, and the application in treatment gout。
In conjunction with the purpose of the present invention, present invention is specifically described。
The present invention has the compound of formula (I) and has following structural formula:
Wherein, R1Selected from H, C1-C5Alkyl, C3-C6Cycloalkyl。
Preferably, R1Selected from C1-C3Alkyl, C3-C4Cycloalkyl。
Further, it is preferable that below general formula (I) compound,
Formula of the present invention (I) compound is synthesized by following route:
Compound II per reacts in the presence of a base with 4-halo butyronitrile III, obtains compound IV；Compound IV in the presence of a base with R2X (V) is obtained by reacting compound VI；Compound VI and NaN3At NH4There is lower reaction in Cl, obtains product VII；VII and compound 2-halogenated acetic acids VIII is obtained by reacting product I in the presence of a base。X is selected from Cl, Br and I, and described alkali is selected from various organic bases, inorganic base etc.。Described R1Defined as described above。
Compound of Formula I of the present invention has the inhibitory action of URAT1, can as effective ingredient for preparing the medicine of hyperuricemia and gout。The activity of compound of Formula I of the present invention is verified by receptor binding assays。
The compound of Formula I of the present invention is effective in comparatively wide dosage range。The dosage that such as every day takes, within the scope of 1mg-500mg/ people, is divided into once or is administered for several times。The actual dosage taking compound of Formula I of the present invention can be determined according to relevant situation by doctor。
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated。It should be noted that following embodiment is only for illustrating, and it is not intended to limit the present invention。Those skilled in the art all should within the protection domain required by the application claim according to the various changes that the teachings of the present invention is made。
The synthesis of embodiment 1 compound I-1
A. the synthesis of compound IV-1
3.76g (20mmol) Compound II per-1 and 2.96g (20mmol) Compound II per I-1 are dissolved in the 40mL DMF dried, stirring, add 3.32g (20mmol) potassium iodide and 6.91g (50mmol) potassium carbonate, nitrogen atmosphere reacts at 100 DEG C, until having reacted (TLC follows the tracks of, general 5h)。After reactant mixture cooling, pour in 300mL frozen water, stirring, use the CH of 100mL × 32Cl2Extracting, merge extraction phase, use the salt water washing of 100mL5%, anhydrous sodium sulfate dries。Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, and the residue obtained uses column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=278 ([M+Na]+)。
B. the synthesis of compound VI-1
3.82g (12mmol) compound IV-1 and 1.12g (12mmol) Celfume V-1 is dissolved in the 30mL DMF dried, stirring, adds 4.98g (36mmol) potassium carbonate, reacts in nitrogen atmosphere at 100 DEG C, until having reacted。After reactant mixture cooling, pour in 300mL frozen water, stirring, use the CH of 100mL × 32Cl2Extracting, merge extraction phase, use the salt water washing of 100mL5%, anhydrous sodium sulfate dries。Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, and the residue obtained uses column chromatography purification, obtains compound VI-1, white solid, ESI-MS, m/z=292 [M+Na]+)。
C. the synthesis of compound VII-1
1.99g (8mmol) compound VI-1 is dissolved in the 20mL DMF dried, stirring, adds 1.30g (20mmol) NaN3With 1.07g (20mmol) ammonium chloride, then reaction at 120 DEG C in nitrogen atmosphere, until having reacted。After reactant mixture cooling, pour in 200mL frozen water, stirring, use the CH of 100mL × 32Cl2Extracting, merge extraction phase, use the salt water washing of 100mL5%, anhydrous sodium sulfate dries。Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, and the residue obtained uses column chromatography purification, obtains compound VII-1, white solid, ESI-MS, m/z=335 [M+Na]+)。
D. the synthesis of compound I-1
1.56g (5mmol) compound VII-1 and 1.39g (10mmol) bromoacetic acid is dissolved in 15mL ethanol, stir under room temperature, the slowly dropping 3mL aqueous solution containing 1.20g (30mmol) NaOH, gained mixture is warming up to 50 DEG C of heating, until having reacted。After reactant mixture cooling, pouring in 100mL frozen water, stirring, concentrated hydrochloric acid regulates pH=2-3, uses the CH of 50mL × 32Cl2Extracting, merge extraction phase, use the salt water washing of 100mL5%, anhydrous sodium sulfate dries。Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, and the residue obtained uses column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=369 ([M-H]-)。
Embodiment 2-5
With reference to embodiment 1 operating procedure, it is prepared for compound listed in Table。
Embodiment 6
Compound of the present invention and related compound are to the URAT1 IC suppressed50It is worth the similar method recorded according to document and measures (in US2014/0005136 embodiment 12)。
Build the cell strain of stably express humanization URAT1 transporter: be subcloned into the plasmid pCMV6/neo (Origene) of eukaryotic expression from plasmid pCMV6-XL-5 (Origene) by humanization URAT1 gene (SLC22A112)。Gene sequencing confirms humanization URAT1 and the information consistent (NM_144585.2) of record in gene bank。HEK293 human embryonic kidney cell (ATCC#CRL-1573) in EMEM tissue culture medium at the CO of 5%2Cultivate with in the air atmosphere of 95%。L2000 type transfection agents (Invitrogene) is used to be transfected on HEK293 cell by pCMV6/Neo/URAT1。After 24 hours, transfected cell is assigned in the tissue culture dishes that diameter is 10cm, continued growth one day, then culture medium is replaced by the fresh culture medium containing 0.5mg/mLG418 (Gibco)。After 8 days, select and collect drug resistance bacterium colony, and right with its test14The transport activity of the uric acid of C-labelling。HEK293/URAT1 cell is planted on 96 orifice plates that poly-D-Lys covers with the density in 75,000/ hole。
These cells grow overnight at 37 DEG C in incubator, are then cooled under room temperature, and culture fluid therein uses the cleanout fluid in 250 μ L/ holes to wash once the 10mMHEPES of pH=7.3 (the 125mM sodium gluconate)。Testing compound or blank are added to containing 40 μMs14In the buffer of C-labelling uric acid (54mCi/mmol), described buffer contains 125mM sodium gluconate, 4.8mM potassium gluconate, 1.2mM potassium dihydrogen phosphate, 1.2mM magnesium sulfate, 1.3mM calcium gluconate, 5.6mM glucose, 25mMHEPES, final pH=7.3。96 orifice plates are at room temperature cultivated 10 minutes, then respectively clean three times with the above-mentioned cleanout fluid in 50 μ L/ holes and 250 μ L/ holes successively。Adding Microscint20 type liquid on 96 orifice plates and dodge agent, plank is overnight incubation at 45 DEG C, then reading on TopCountPlateReader, and calculates IC accordingly50。
Shown in the following list of result。
The part of compounds of the present invention IC to URAT150Value
| Compound | IC50(hURAT1,nM) |
| Embodiment 1 compound | 5.5 |
| Embodiment 2 compound | 8.3 |
| Embodiment 3 compound | 14.2 |
| Embodiment 4 compound | 10.7 |
| Embodiment 5 compound | 12.9 |
Above-mentioned IC50Measurement result show, the compound of the present invention is strong URAT1 inhibitor, it is possible to be used for preparing treatment hyperuricemia and the medicine of gout。
Claims (4)
1. there is the compound of general formula I,
Wherein, R1Selected from H, C1-C5Alkyl, C3-C6Cycloalkyl。
2. the compound with formula I that claim 1 is defined,
Wherein, R1Selected from C1-C3Alkyl, C3-C4Cycloalkyl。
3. the compound of Formula I that claim 2 is defined, is selected from:
4. the compound of Formula I defined for one of claim 1-3 application in preparation treatment hyperuricemia and gout medicine。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410525880.4A CN104292175B (en) | 2014-10-07 | 2014-10-07 | Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410525880.4A CN104292175B (en) | 2014-10-07 | 2014-10-07 | Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104292175A CN104292175A (en) | 2015-01-21 |
| CN104292175B true CN104292175B (en) | 2016-06-22 |
Family
ID=52312164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410525880.4A Expired - Fee Related CN104292175B (en) | 2014-10-07 | 2014-10-07 | Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104292175B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356977A (en) * | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | Glucagon antagonists/inverse agonists |
| WO2008021804A2 (en) * | 2006-08-09 | 2008-02-21 | Allergan, Inc. | Therapeutic amides and related compounds |
| EP1985297A1 (en) * | 2006-01-27 | 2008-10-29 | Japan Tobacco, Inc. | Carboxylic acid compound and use thereof |
| US20100056542A1 (en) * | 2008-09-04 | 2010-03-04 | Ardea Biosciences | Compounds, compositions and methods of using same for modulating uric acid levels |
-
2014
- 2014-10-07 CN CN201410525880.4A patent/CN104292175B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356977A (en) * | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | Glucagon antagonists/inverse agonists |
| EP1985297A1 (en) * | 2006-01-27 | 2008-10-29 | Japan Tobacco, Inc. | Carboxylic acid compound and use thereof |
| WO2008021804A2 (en) * | 2006-08-09 | 2008-02-21 | Allergan, Inc. | Therapeutic amides and related compounds |
| US20100056542A1 (en) * | 2008-09-04 | 2010-03-04 | Ardea Biosciences | Compounds, compositions and methods of using same for modulating uric acid levels |
| CN103819419A (en) * | 2008-09-04 | 2014-05-28 | 亚德生化公司 | Compounds, compositions and methods of using same for modulating uric acid levels |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104292175A (en) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104292123B (en) | The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use | |
| CN104262277B (en) | Containing nitro and the tetrazoleacetic acid compounds of halobenzene replacement, Preparation Method And The Use | |
| CN104292178B (en) | Containing tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104311442B (en) | The succinamide derivative of halo naphthalene nucleus, Preparation Method And The Use | |
| CN104292175B (en) | Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use | |
| CN104292177B (en) | Nitrile group-containing and halobenzene substituted tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104230833B (en) | The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use | |
| CN104341362B (en) | Triazole sulphonyl malonic acid compounds, Preparation Method And The Use | |
| CN104370841B (en) | Triazole sulfenyl malonic acid compounds, Preparation Method And The Use | |
| CN104370842B (en) | The triazole sulphonyl malonic acid compounds of phenyl replacement, Preparation Method And The Use | |
| CN104262276B (en) | Tetrazoleacetic acid compounds containing halogeno-benzene, Preparation Method And The Use | |
| CN104326999B (en) | Alkoxy-substituted triazole sulfinyl malonate type compound, and preparation method and application thereof | |
| CN104341361B (en) | Cyano-substituted triazolesulfonylmalonic acid compounds as well as preparation method and application thereof | |
| CN104326997B (en) | Alkoxyl substituted triazole malonic acid compounds, Preparation Method And The Use | |
| CN104341364A (en) | Triazole malonic acid compounds as well as preparation method and application thereof | |
| CN104326993B (en) | A kind of nitro substituted 1,2,4-triazole sulfenyl malonic acid compounds, Preparation Method And The Use | |
| CN104326998B (en) | Phenyl substituted triazole malonic acid compounds, Preparation Method And The Use | |
| CN104311498B (en) | Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces | |
| CN104193644B (en) | The succinamide derivative of methoxy naphthalene nucleus, Preparation Method And The Use | |
| CN104327000B (en) | Phenyl substituted triazole sulfenyl malonic acid compounds, Preparation Method And The Use | |
| CN104311445B (en) | Naphthalene-ring containing succinamide derivative, Preparation Method And The Use | |
| CN104341363B (en) | A kind of nitro substituted triazole sulphonyl malonic acid compounds, Preparation Method And The Use | |
| CN104370843B (en) | Halo triazole sulfenyl malonic acid compounds, Preparation Method And The Use | |
| CN104326995A (en) | Nitrile-substituted triazole malonate type compound, and preparation method and application thereof | |
| CN104292176B (en) | A kind of tetrazoleacetic acid compounds containing halogeno-benzene, Preparation Method And The Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181226 Address after: Room 204-209, Science and Technology Entrepreneurship Park, Jiefangnan Road Mining University, Xuzhou City, Jiangsu Province, 221000 Patentee after: Li Gui Address before: 528000 floor 5, Pu Lan Road, Chancheng District, Foshan, Guangdong. Patentee before: Zhang Yuanqiang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190801 Address after: 518000 No. 4023, Guangda Road, No. 57, Yuanshan Street Security Community, Longgang District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Ying'an Sports Biotechnology Co.,Ltd. Address before: Room 204-209, Science and Technology Entrepreneurship Park, Jiefangnan Road Mining University, Xuzhou City, Jiangsu Province, 221000 Patentee before: Li Gui |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160622 Termination date: 20211007 |